14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BRO vs WST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Brown & Brown, Inc. (BRO) is the stronger overall head-to-head candidate over West Pharmaceutical Services, Inc. (WST) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BRO carries a Unified Composite Score of 44.0/100 (HOLD) at $73.07 (15.4x Forward P/E, 26.8% operating margin), whereas WST carries 33.2/100 (SELL) at $390.30 (37.5x Forward P/E, 22.9% operating margin).
Competes within the Insurance Brokers value chain with $24.0B market capitalization and 26.8% operating margin.
OpEx & R&D Reinvestment23.0% of Rev ($1.57B)
90D Engineering Disclosures0 Published
WST Moat ProfileScale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $27.6B market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment14.7% of Rev ($499M)
90D Engineering Disclosures0 Published
Investor FAQ BRO vs WST Key Questions & Quantitative Answers
As of Nov 20, 2026, Brown & Brown, Inc. (BRO) is the stronger overall head-to-head candidate over West Pharmaceutical Services, Inc. (WST) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BRO carries a Unified Composite Score of 44.0/100 (HOLD) at $73.07 (15.4x Forward P/E, 26.8% operating margin), whereas WST carries 33.2/100 (SELL) at $390.30 (37.5x Forward P/E, 22.9% operating margin). Technically, BRO sits in a Neutral phase (RSI 57.3, CONSOLIDATION options structure) and WST sits in a Neutral phase (RSI 43.2, UNCLASSIFIED options structure).
BRO leads the Growth & Scale pillar: BRO posts +9.7% YoY revenue growth and -1.0% YoY earnings growth on $6.81B TTM revenue (49.8% gross margin, 26.8% operating margin), compared with WST at +8.7% YoY revenue growth and +57.3% YoY earnings growth on $3.40B TTM revenue (37.6% gross margin, 22.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BRO cumulative revenue shifted +193.5% while WST shifted +78.5%. In operating R&D and SG&A reinvestment, BRO deploys 23.0% of Rev ($1.57B) (0 90-day corporate R&D disclosures) versus 14.7% of Rev ($499M) (0 disclosures) for WST.
BRO screens cheaper on headline valuation multiples. BRO trades at 15.4x Forward P/E, 23.0x Trailing P/E, 1.88x PEG, and 4.5x EV/Revenue (21.8% FCF margin), whereas WST trades at 37.5x Forward P/E, 44.5x Trailing P/E, 2.94x PEG, and 8.1x EV/Revenue (13.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BRO (9.8% ROE) versus WST (21.2% ROE) capital efficiency.
In options market volatility and institutional positioning, BRO carries 30.8% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.48β · 38% Vol realized risk). By comparison, WST carries 28.2% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 27% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.